Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Phase 2 trial to explore the efficacy and safety of irinotecan (CPT-11). Also administered at
each cycle was zofran/Kytril/Anzemet, decadron, and IV atropine.
At each cycle, patient exams and interviews as well as lab results were to help the research
team to determine the symptomatic side effects of the treatment. Recorded past toxicities
were to be compared with current side effects.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute